|drug239||Anti-SARS-CoV-2 IgT seropositivity Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.03|
There is one clinical trial.
COVID-19, which emerged in China in December 2019, has become a pandemic with its spread to many countries of the world. Mortality rates of COVID-19 pandemics vary between countries. It is known that mortality based on COVID-19 is higher in old population. Therefore the aim of this study to analyze the experience of 7 governmental hospitals in terms of patient characteristics, possible risk factors of mortality based on COVID-19.
Description: mortality based on COVID-19 within the patients aged between 18-50 will be evaluatedMeasure: mortality based on COVID-19 Time: 3 months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports